<DOC>
	<DOCNO>NCT02232633</DOCNO>
	<brief_summary>This open label , multi-center , phase II study BBI503 administer adult patient advance hepatobiliary cancer exhaust currently approve standard anti-cancer treatment option . BBI503 administer orally , daily , continuous 28-day cycle dose 300 mg daily . Cycles repeat patient longer clinically benefit therapy . Safety , efficacy tolerability BBI503 assess duration study treatment .</brief_summary>
	<brief_title>A Study BBI503 Adult Patients With Advanced Hepatobiliary Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPPA ) prior studyspecific screening procedure Histologically cytologically confirm hepatocellular carcinoma cholangiocarcinoma , metastatic , unresectable , recurrent ; currently approve , standard anticancer treatment option available . Patients must receive standard care treatment prior enrollment . ≥ 18 year age Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI503 dose Females childbearing potential must negative serum pregnancy test Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) ≤ 5.0x upper limit normal ( ULN ) Hemoglobin &gt; 8.0 g/dL Total bilirubin ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN creatinine clearance &gt; 50 mL/min accord CockcroftGault estimation . Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 60 x 10^9/L Life expectancy ≥ 3 month A patient hepatocellular carcinoma ( HCC ) arise medical context must also meet follow criterion : Must candidate potentially curative resection Must ChildPugh class A B7 ( i.e. , order eligible , total ChildPugh score patient must ≤ 7 ) Must receive prior treatment sorafenib ; either disease progression treatment document intolerance sorafenib treatment sorafenib possible . Patients uncontrolled massive ascites presence hepatic encephalopathy within four ( 4 ) week first dose exclude A patient confirm cholangiocarcinoma type must also meet follow criterion : Must disease amenable surgical , radiation , combine modality therapy curative intent Must receive prior treatment gemcitabine , either alone combination platinum agent . Patients eligible gemcitabine must receive alternate firstline systemic chemotherapy regimen Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose BBI503 . Patients may begin BBI503 date determine investigator medical monitor sponsor provide minimum 7 day since last receiving anticancer treatment , prior treatmentrelated adverse event ( AEs ) resolve deem irreversible . Major surgery within 4 week prior first dose ( require general anesthesia and/or inpatient hospitalization recovery ) . Any known symptomatic untreated brain metastasis require increase steroid dose within 2 week prior start study . Patients treat brain metastasis must stable 4 week completion treatment . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . Pregnant breastfeeding Significant gastrointestinal disorder ( ) , opinion treat investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small intestine resection ) ; absorption oral medication may impair . Unable unwilling swallow BBI503 capsule daily Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement ( e.g . reliable transportation ) . Subjects history another primary cancer , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor know active disease present opinion investigator affect patient outcome set current hepatobiliary malignancy . Abnormal ECGs clinically significant QT prolongation QTc &gt; 480 msec , clinically significant cardiac enlargement hypertrophy , new bundle branch block , sign active ischemia . Patients evidence prior infarction New York Heart Association ( NYHA ) functional class II , III , IV exclude , patient mark arrhythmia Wolff Parkinson White pattern complete atrioventricular ( AV ) dissociation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>